These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 28392551)

  • 21. The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients.
    Jiang R; Zou X; Hu W; Fan YY; Yan Y; Zhang MX; You R; Sun R; Luo DH; Chen QY; Huang PY; Hua YJ; Guo L; Chen MY
    Tumour Biol; 2015 Sep; 36(10):7775-87. PubMed ID: 25944165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy.
    Tao CJ; Chen YY; Jiang F; Feng XL; Jin QF; Jin T; Piao YF; Chen XZ
    Oncotarget; 2016 Jul; 7(29):46653-46661. PubMed ID: 27270307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of MRI-derived masticator space involvement in IMRT-treated nasopharyngeal carcinoma patients.
    Xiao Y; Pan J; Chen Y; Lin S; Chen Y; Zong J; Fang Y; Guo Q; Chen B; Tang L
    Radiat Oncol; 2015 Sep; 10():204. PubMed ID: 26407897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
    Liang SB; Teng JJ; Hu XF; Yang XL; Luo M; Fang XN; Liu DS; Chen Y; Fu LW
    BMC Cancer; 2017 Jul; 17(1):506. PubMed ID: 28754109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area.
    Yao JJ; Zhu FT; Dong J; Liang ZB; Yang LW; Chen SY; Zhang WJ; Lawrence WR; Zhang F; Wang SY; Sun Y; Zhou GQ
    BMC Cancer; 2019 Jan; 19(1):37. PubMed ID: 30621619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Hong X; Wang G; Xu G; Shi W; Wang T; Rong Z; Mo C
    Medicine (Baltimore); 2022 Jan; 101(3):e28507. PubMed ID: 35060503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment.
    Lv X; Xiang YQ; Cao SM; Qian CN; Li NW; Guo L; Mai HQ; Chen QY; Huang PY; Luo D; Cao KJ; Hong MH; Guo X
    Head Neck; 2011 Jun; 33(6):780-5. PubMed ID: 20967862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer.
    Cho O; Oh YT; Chun M; Noh OK; Hoe JS; Kim H
    Head Neck; 2016 Apr; 38 Suppl 1():E1061-7. PubMed ID: 26040623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
    Tang LQ; Hu DP; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Wen SH; Peng YT; Chen WH; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mai HQ
    PLoS One; 2015; 10(4):e0122965. PubMed ID: 25874450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic value of pretreatment tumor apparent diffusion coefficient values in nasopharyngeal carcinoma.
    Yan DF; Zhang WB; Ke SB; Zhao F; Yan SX; Wang QD; Teng LS
    BMC Cancer; 2017 Oct; 17(1):678. PubMed ID: 29020937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.
    Xiong Y; Shi LL; Zhu LS; Peng G
    Ann Palliat Med; 2021 Apr; 10(4):4122-4133. PubMed ID: 33832314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.
    Liu LT; Liang YJ; Guo SS; Xie Y; Jia GD; Wen DX; Tang LQ; Chen QY; Mai HQ
    Head Neck; 2022 Jan; 44(1):34-45. PubMed ID: 34636116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognoses and long-term outcomes of nasopharyngeal carcinoma in Han and Uyghur patients treated with intensity-modulated radiotherapy in the Xinjiang Autonomous Region of China.
    Wang R; Tan Y; Wang X; Ma L; Wang D; Hu Y; Qin Y; Liu K; Chang C; Yu J
    PLoS One; 2014; 9(11):e111145. PubMed ID: 25375129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma.
    Li J; Jiang R; Liu WS; Liu Q; Xu M; Feng QS; Chen LZ; Bei JX; Chen MY; Zeng YX
    PLoS One; 2013; 8(12):e83069. PubMed ID: 24386144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
    Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
    You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
    Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.